William Blair analyst Andy Hsieh has maintained their bullish stance on CRBP stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors related to the promising trial results of Corbus Pharmaceuticals’ CRB-701, an antibody-drug conjugate targeting nectin-4. The Phase I/II trial data presented at the ESMO annual meeting demonstrated impressive activity in heavily pretreated populations with bladder, cervical, and head and neck cancers, particularly in the head and neck cancer cohort where response rates exceeded expectations.
Furthermore, CRB-701 showed a differentiated safety profile compared to existing treatments, with less frequent and severe neuropathy and skin toxicity, although ocular toxicity remains a concern. The potential of CRB-701 to fill a therapeutic gap in the second-line setting for head and neck cancer, independent of EGFR-targeting modalities, positions it well for future market opportunities. These factors collectively underpin Hsieh’s positive outlook and Buy rating for Corbus Pharmaceuticals.
Hsieh covers the Healthcare sector, focusing on stocks such as Skye Bioscience, Viking Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, Hsieh has an average return of 8.2% and a 45.54% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.